PRAMEing a picture of differentiation therapy for AML?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23532884.
- Also identified by DOI 10.1158/1078-0432.CCR-13-0386.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Addition of retinoic acid to chemotherapy improves survival of patients with acute myeloid leukemia. This effect is more pronounced in leukemias that express high levels of PRAME. PRAME is an inhibitor of retinoic acid signaling, which may prove to be an important marker for retinoic acid response.
Medical subject headings
- Antigens, Neoplasm
- Antineoplastic Combined Chemotherapy Protocols
- Cell Differentiation
- Leukemia, Myeloid, Acute
- Receptors, Retinoic Acid
- Tretinoin